Garland, Keira published the artcileOptimization of globomycin analogs as novel gram-negative antibiotics, COA of Formula: C25H23NO4, the publication is Bioorganic & Medicinal Chemistry Letters (2020), 30(20), 127419, database is CAplus and MEDLINE.
Discovery of novel classes of Gram-neg. antibiotics with activity against multi-drug resistant infections is a critical unmet need. As an essential member of the lipoprotein biosynthetic pathway, lipoprotein signal peptidase II (LspA) is an attractive target for antibacterial drug discovery, with the natural product inhibitor globomycin offering a modestly-active starting point. Informed by structure-based design, the globomycin depsipeptide was optimized to improve activity against E. coli. Backbone modifications, together with adjustment of physicochem. properties, afforded potent compounds with good in vivo pharmacokinetic profiles. Optimized compounds such as (I) (E. coli MIC 3.1μM) and (II) (E. coli MIC 0.78μM) demonstrate broad spectrum activity against gram-neg. pathogens and may provide opportunities for future antibiotic discovery.
Bioorganic & Medicinal Chemistry Letters published new progress about 77128-73-5. 77128-73-5 belongs to ethers-buliding-blocks, auxiliary class Inhibitor, name is (S)-2-((((9H-Fluoren-9-yl)methoxy)carbonyl)(methyl)amino)-3-phenylpropanoic acid, and the molecular formula is C25H23NO4, COA of Formula: C25H23NO4.
Referemce:
https://en.wikipedia.org/wiki/Ether,
Ether | (C2H5)2O – PubChem